- Title
- 628P Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?
- Creators
- M.K. Hardwick - Targeted Medical Pharma (United States)E. Esplin - Invitae (United States)B. Mazzerelli - Clinical, Urology Austin, Austin, TX, USAD. Morris - Urology AssociatesS. Heron - Advanced DermatologyJ. Veys - Georgia UrologyA. Engelman - Clinical, Cancer Center of South Tampa, Tampa, FL, USAP. Dato - Genesis HealthCareR. Bevan-Thomas - Urology Associates of North TexasD. Wise - NYU Langone HealthR. Cornell - DermSurgery AssociatesA. Berger - Clinical, Associated Urological Specialists, Chicago Ridge, IL, USAS. Nielsen - Invitae (United States)K. Hatchell - Invitae (United States)R. Nussbaum - Invitae (United States)M. Gazi - Urology AssociatesC.M. Pieczonka - Department of Oncology, Associated Medical Professionals of NY, Syracuse, NY, USAL. Belkoff - Clinical, Midatlantic Urology, Bala Cynwyd, PA, USAD.J. Cahn - Research, Colorado Urology, Lakewood, CO, USAN.D. Shore - Carolina Urologic Research Center
- Publication Details
- Annals of oncology, v 32, pp S663-S663
- Publisher
- Elsevier; AMSTERDAM
- Number of pages
- 1
- Grant note
Invitae.
- Resource Type
- Abstract
- Language
- English
- Academic Unit
- Surgery
- Web of Science ID
- WOS:000700527701094
- Other Identifier
- 991021916912104721
Abstract
628P Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?
Annals of oncology, v 32, pp S663-S663
Sep 2021
Metrics
4 Record Views
Details
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology